Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil

Published Phase 1 data in Sexual Medicine strengthen the scientific foundation for Daré Bioscience’s proprietary topical Sildenafil Cream, 3.6%

At the 71 mg topical dose, mean maximum plasma concentration of sildenafil was approximately 187-fold lower than following a 50 mg oral dose